{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:57:56Z","timestamp":1791867476660,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.ygyno.2011.10.003","type":"journal-article","created":{"date-parts":[[2011,11,5]],"date-time":"2011-11-05T02:04:12Z","timestamp":1320458652000},"page":"221-224","source":"Crossref","is-referenced-by-count":39,"title":["Effect of chemotherapy delays and dose reductions on progression free and overall survival in the treatment of epithelial ovarian cancer"],"prefix":"10.1016","volume":"124","author":[{"given":"C.I.","family":"Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.J.","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Hade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.E.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.L.","family":"Eisenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Salani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2011.10.003_bb0005","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ygyno.2011.10.003_bb0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1471-0528.2008.02033.x","article-title":"The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma","volume":"116","author":"Gerestein","year":"2009","journal-title":"BJOG"},{"key":"10.1016\/j.ygyno.2011.10.003_bb0015","series-title":"SEER cancer statistics review","author":"Horner","year":"1975"},{"issue":"Suppl. 3","key":"10.1016\/j.ygyno.2011.10.003_bb0020","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6601494","article-title":"Primary ovarian cancer chemotherapy: current standards of care","volume":"89","author":"McGuire","year":"2003","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ygyno.2011.10.003_bb0025","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ygyno.2011.10.003_bb0030","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1991.9.7.1138","article-title":"Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology group experience","volume":"9","author":"Omura","year":"1991","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ygyno.2011.10.003_bb0035","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ygyno.2007.02.015","article-title":"Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care","volume":"105","author":"Fung-Kee-Fung","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.ygyno.2011.10.003_bb0040","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"282","key":"10.1016\/j.ygyno.2011.10.003_bb0045","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"2","key":"10.1016\/j.ygyno.2011.10.003_bb0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"3","key":"10.1016\/j.ygyno.2011.10.003_bb0055","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1006\/gyno.2001.6328","article-title":"Identification of prognostic factors in advanced epithelial ovarian carcinoma","volume":"82","author":"Chi","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2011.10.003_bb0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2000.18.1.106","article-title":"Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study","volume":"18","author":"Muggia","year":"2000","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2011.10.003_bb0065","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/0360-3016(95)00220-S","article-title":"Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy","volume":"32","author":"Perez","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"34","key":"10.1016\/j.ygyno.2011.10.003_bb0070","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group Trials","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ygyno.2011.10.003_bb0075","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJM199405053301801","article-title":"Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma","volume":"330","author":"Wood","year":"1994","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ygyno.2011.10.003_bb0080","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199504063321401","article-title":"Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer","volume":"332","author":"Bonadonna","year":"1995","journal-title":"N Engl J Med"},{"issue":"S1","key":"10.1016\/j.ygyno.2011.10.003_bb0085","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0959-8049(99)00259-2","article-title":"Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer","volume":"36","author":"Chang","year":"2000","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2011.10.003_bb0090","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/sj.bjc.6601279","article-title":"Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients","volume":"89","author":"Leonard","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2011.10.003_bb0095","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2007.04.012","article-title":"Response and outcomes in elderly patients with stages IIIC\u2013IV ovarian cancer receiving platinum-taxane chemotherapy","volume":"106","author":"Eisenhauer","year":"2007","journal-title":"Gynecol Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811008158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811008158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T20:26:01Z","timestamp":1741897561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811008158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0090825811008158"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.10.003","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}